You are here:
TRIADIMEFON, A TRIAZOLE FUNGICIDE, INDUCES STEREOTYPED BEHAVIOR AND ALTERS MONOAMINE METABOLISM IN RATS
Citation:
Walker, Q., M. Lewis, K. Crofton, AND R. Mailman. TRIADIMEFON, A TRIAZOLE FUNGICIDE, INDUCES STEREOTYPED BEHAVIOR AND ALTERS MONOAMINE METABOLISM IN RATS. U.S. Environmental Protection Agency, Washington, D.C., EPA/600/J-90/041 (NTIS PB90217530).
Description:
Triadimefon, a triazole fungicide, has been observed to increase locomotion and induce stereotyped behavior in rodents. he present experiments characterized the stereotyped behavior induced by triadimefon using a computer-supported observational method, and tested the hypothesis that these effects involved central dopaminergic systems. dult male and female Sprague-Dawley rats vere injected vith triadimefon (0, 50, 100, 200 mg/kg) in corn oil (2 mL/kg ip) four hours prior to behavioral assessment. he two lowest doses of triadimefon increased the frequency of locomotion and rearing, while the highest dose induced highly stereotyped behaviors including backward locomotion, circling, and head weaving. mmediately after behavioral testing, the rats vere sacrificed, and the striata (STR) and olfactory tubercles (OT), terminal fields of the nigrostriatal and mesolimbic dopamine systems, respectively, were dissected. teady-state concentrations of dopamine (DA), serotonin (5-HT), and their metabolites vere determined by HPLC-EC. n independent experiments, the direct in vitro effects of triadimefon on dopamine (D1 and D2) receptor binding and dopamine-sensitive adenylate cyclase activity vere assessed in rat striata. A concentrations vere increased in OT, but decreased in STR. oncentrations of the metabolite 5-HT (5-HIAA) were increased only in STR, and only in animals treated vith 200 mg/kg of triadimefon. n vitro, triadimefon neither competed with D1 or D2 dopaminergic radioligands, nor affected dopamine-stimulated adenylate cyclase activity. ogether these behavioral and biochemical data indicated that triadimefon has actions similar to those produced by indirect acting dopamine agonists.